Poniard Pharmaceuticals, Inc.
PARD · OTC
12/31/2010 | 12/31/2009 | 12/31/2008 | 12/31/2007 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $1,603 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $7,975 | $25,739 | $34,714 | $23,373 |
| G&A Expenses | $17,140 | $14,698 | $14,443 | $0 |
| SG&A Expenses | $17,140 | $14,698 | $12,840 | $12,085 |
| Sales & Mktg Exp. | $0 | $0 | $982 | $0 |
| Other Operating Expenses | $2,843 | $2,541 | $0 | -$105 |
| Operating Expenses | $27,958 | $42,978 | $49,157 | $35,353 |
| Operating Income | -$27,958 | -$42,978 | -$49,157 | -$35,353 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $27,958 | $42,978 | $592 | $2,676 |
| Pre-Tax Income | $0 | $0 | $0 | $0 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$30,051 | -$45,715 | -$48,565 | -$32,782 |
| % Margin | – | – | – | – |
| EPS | -26.4 | -52.4 | -56.4 | -43.2 |
| % Growth | 49.6% | 7.1% | -30.6% | – |
| EPS Diluted | -26.4 | -52.4 | -56.4 | -43.2 |
| Weighted Avg Shares Out | 1,172 | 882 | 867 | 769 |
| Weighted Avg Shares Out Dil | 1,172 | 882 | 867 | 769 |
| Supplemental Information | – | – | – | – |
| Interest Income | $117 | $406 | $2,489 | $4,298 |
| Interest Expense | $2,210 | $3,143 | $1,897 | $1,727 |
| Depreciation & Amortization | $1,313 | $1,470 | $1,603 | $1,526 |
| EBITDA | -$25,019 | -$38,967 | -$47,554 | -$29,529 |
| % Margin | – | – | – | – |